PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma

Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcino...

February 16, 2021

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

February 16, 2021

Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

February 16, 2021

AstraZeneca and Serum Institute of India's COVID-19 Vaccine Receive WHO's EUA to Prevent COVID-19

AstraZeneca and Serum Institute of India's COVID-19 Vaccine Receive WHO's EUA to Prevent COVID-19

February 16, 2021

Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer's Disease

Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer's Disease

February 16, 2021

Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

February 16, 2021

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us